Candidate antiviral and symptomatic therapeutics
Candidate antiviral therapeutics
The following section contains a selection of small organic-molecule/peptide based antiviral drug candidates with potential activity against SARS-CoV-2. Appearance of a compound in the list does not imply any assessment on effectiveness. Because research is rapidly evolving, this list is non-exhaustive. The focus was set on compounds that are advanced in clinical trials. The hits retrieved for a specific query contain patent families relating to the specific drug and also to drugs with a similar chemical structure which are classified in the same class. This is a consequence of the “OR” operator between the classes and key-words used.
- Drug candidates A-C
- Drug candidates D-H
- Drug candidates I-P
-
- IDX-184
- Imatinib
- Indinavir
- Interferon
- ivermectin
- Ledipasvir
- Maribavir
- Mefloquine hydrochloride (Lariam)
- Montelukast
- MP0420 (Ensovibep)
- Molnupiravir
- Nelfinavir
- Neurosivir
- Niclosamide
- Nirmatrelvir/ritonavir (Paxlovid®)
- Nitazoxanide
- Oseltamivir
- Peramivir
- Photofrin
- pHOXWELL protectant
- plitidepsin
- Polydatin
- Presatovir
- Proxalutamide (GT-0918)
- PTC299(Emvododstat)
- PX-12
- Drug candidates Q-Z
Candidate symptomatic therapeutics
The following section contains a selection of small organic-molecule/peptide based drug candidates which may potentially have a beneficial effect on the symptoms of SARS-CoV-2 in infected patients. This list does not cover therapeutics for post-COVID conditions, but rather focuses on acute symptomatic COVID-19 therapies. Appearance of a compound in the list does not imply any assessment on effectiveness. Because research is rapidly evolving, this list is non-exhaustive. The hits retrieved for a specific query contain patent families relating to the specific drug and also to drugs with a similar chemical structure which are classified in the same class. This is a consequence of the “OR” operator between the classes and key-words used. (Each of the listed drug candidates includes a hyperlink to Espacenet and the search statement)
- Acalabrutinib
- Alpha-lipoic acid
- Anakinra
- AMY-101
- Apixaban
- Apremilast
- Argatroban
- Artemisinin
- Asunercept
- Atorvastatin
- Baricitinib
- Bemiparin (Hibor)
- Bucillamine
- Budesonide
- Budesonide/Formoterol fumarate (Symbicort)
- Calcifediol
- Cenicriviroc
- Baricitinib
- Cepharanthine
- Clopidogrel
- Colchicine
- Cyclosporin
- Cysteamine (NM002)
- Dexamethasone
- Dipyridamole
- Eclitasertib
- Enoxaparin
- Enpatoran
- Eritoran
- Erlotinib
- Famotidine
- Fedratinib
- Fingolimod
- Flutamide
- Fluticasone propionate
- Fondaparinux
- Fostamatinib
- HC-1119 (H3 enzalutamide)
- Heparin
- Hydrocortisone
- Icosapent ethyl (Vascepa)
- IMU-838
- Interferon
- Lenalidomide
- Losartan
- Macrolides, e.g. azithromycin
- Methylprednisolone
- MK-7110
- N115 (sodium pyruvate)
- N-acetylcysteine
- Nimesulide
- Nintedanib
- Novaferon
- Opaganib
- Prednisone
- Pulm-001 (dapsone)
- Reparixin
- Rivaroxaban (Xarelto)
- Ruxolitinib
- Sunitinib
- Tofacitinib (Xeljanz)
- Tradipitant
- Valsartan
- VP01
- Ulinastatin
- Zanubrutinib
- Zilucoplan
Patent analytics gives a deeper dive into the patent landscape. Our patent analysts have created a spreadsheet containing all the search strategies and datasets for patents for antiviral and symptomatic therapeutics for fighting coronavirus, as well as additional statistics in one place for you to download. You can also run the search strategies on your own platform or analyse the datasets yourself. If you are not familiar with how to write or adapt search strategies, our Espacenet pocket guide will help.
The use of the EPO’s website, downloads, data and information tools are subject to the EPO’s standard terms and conditions. See especially the terms of use for Espacenet.